Unleashing the Power of Targeted Immunotherapies
for Cancer

About us

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win® technology platform.

Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Latest news

IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent

IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent